Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458553 | 0.82 | ALDH1A1 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13430817 | 0.81 | HDAC3 (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11981899 | 0.79 | RNPEP (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25923045 | 0.78 | NAAA (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18307314 | 0.78 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23228276 | 0.77 | HDAC3 (0.34) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Ethylene Glycol Diisobutanoate SCHEMBL843146 | 0.77 | TSHR (0.36) | TSHR | |
| SCHEMBL12285540 | 0.77 | TSHR (0.53) | METAP2TSHR | |
| SCHEMBL25755665 | 0.77 | MMP1 (0.37) | METAP2TSHRACHE | |
| SCHEMBL25679031 | 0.76 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180008719-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20170362346-A1 | METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES | CERULEAN PHARMA INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9610360-B2 | Polymer drug conjugates with tether groups for controlled drug delivery | CERULIEAN PHARMA INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160166567-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058875-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150141638-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110282047-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110245201-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110160159-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | HDAC3 1573/4885HDAC4 2672/4885HDAC1 2187/4885 |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | HDAC3 3592/4885HDAC4 4323/4885HDAC1 4404/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | HDAC3 1573/4885HDAC4 2672/4885HDAC1 2187/4885 |
| US-20180008719-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | CD44, MSN, ABCB1 | HDAC3 541/4885HDAC4 850/4885HDAC1 1894/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | HDAC3 625/4885HDAC4 1175/4885HDAC1 720/4885 |
| US-20160166567-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | HDAC3 2619/4885HDAC4 1870/4885HDAC1 2005/4885 |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | CD47, SDCBP, BST2 | HDAC3 146/4885HDAC4 481/4885HDAC1 592/4885 |
| US-20150141638-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | HDAC3 1937/4885HDAC4 2529/4885HDAC1 2542/4885 |
| US-20110160159-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | HDAC3 2619/4885HDAC4 1870/4885HDAC1 2005/4885 |
| US-20110245201-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | HDAC3 2619/4885HDAC4 1870/4885HDAC1 2005/4885 |
| US-20160058875-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | HDAC3 2619/4885HDAC4 1870/4885HDAC1 2005/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | HDAC3 1767/4885HDAC4 2118/4885HDAC1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.